Compass Therapeutics (CMPX) Equity Ratio (2022 - 2026)
Compass Therapeutics' Equity Ratio history spans 5 years, with the latest figure at 0.91 for Q1 2026.
- On a quarterly basis, Equity Ratio rose 8.34% to 0.91 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.91, a 8.34% increase, with the full-year FY2025 number at 0.9, changed 0.47% from a year prior.
- Equity Ratio hit 0.91 in Q1 2026 for Compass Therapeutics, up from 0.9 in the prior quarter.
- Over the last five years, Equity Ratio for CMPX hit a ceiling of 0.97 in Q1 2024 and a floor of 0.8 in Q2 2025.
- Historically, Equity Ratio has averaged 0.91 across 5 years, with a median of 0.92 in 2022.
- Biggest five-year swings in Equity Ratio: dropped 14.93% in 2025 and later grew 8.34% in 2026.
- Tracing CMPX's Equity Ratio over 5 years: stood at 0.91 in 2022, then grew by 4.07% to 0.95 in 2023, then dropped by 5.8% to 0.89 in 2024, then grew by 0.47% to 0.9 in 2025, then rose by 1.42% to 0.91 in 2026.
- Business Quant data shows Equity Ratio for CMPX at 0.91 in Q1 2026, 0.9 in Q4 2025, and 0.91 in Q3 2025.